Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments

• Andere auteurs: Uchino, Junji (Redacteur)
• Formaat: Elektronisch Hoofdstuk
• Taal: Engels
• Gepubliceerd in: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
• Onderwerpen: Medicine; non-small cell lung cancer; previously treated patients; phase I/II trial; chemotherapy; docetaxel; S-1; immunotherapy; rechallenge; retrospective analysis; pulmonary pleomorphic carcinoma; prognostic factor; glucose transporter 1; lung cancer; multiple cancers; metastasis; sequencing; mutation; genomic diagnosis; FDG-PET; immune checkpoint inhibitor; PD-1; prognosis; RAD51B methylation; PD-L1 expression; predictive biomarker; PD-1 blockade; interstitial lung disease; pulmonary fibrosis; radiology and other imaging; non-small-cell lung cancer; epidermal growth factor receptor; tyrosine kinase inhibitors; TP53 mutations; responsiveness; targeted therapy; network meta-analysis; stage IIIA-N2; surgery; immune checkpoint inhibitors; biomarker; nonsmall cell lung cancer; HIP1R; PD-L1; RUNX1; methylation; survival; EGFR-TKI; T790M; osimertinib; immune-related adverse events; endocrine disorders; tumor-bearing patients; PD-1 inhibitors; PD-L1 inhibitors; meta-analysis; nivolumab; Expanded Access Program; real-world data; daily practice; prognostic factors; NSCLC; KRAS; DNA polymerase beta; platinum-based first-line; adjuvant chemotherapy; β-catenin; lung neoplasms; nucleotide-diphosphate kinase; recurrence; unresectable; salvage surgery; oligometastasis
• Online toegang: DOAB: download the publication; DOAB: description of the publication

Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed. Cancer cases that were highly responsive to gefitinib were later discovered to have epithelial growth factor receptor (...